Study maps vaccine for deadly pathogenic fungus

May 31, 2012

University of Alberta researchers have made breakthrough use of 3-D magnetic resonance technology to map the structure of a common fungus that is potentially deadly for individuals with impaired immune function. The work could pave the way for development of an effective vaccine.

The researchers targeted Candida, a pathogen that in its most virulent form has led to more than 70,000 in North American . Health officials estimate that death rate from this bloodstream infection is 40 per cent.

Lead U of A researchers Margaret Johnson and David Bundle as well as collaborators, at the Alberta Glycomics Centre, used for a three-dimensional examination of the fungus at an that measures less than 100 millionth of a centimetre.

The process, called molecular recognition allowed researchers to examine carbohydrate and antibody molecules related to the fungus to determine what sort of vaccine can best combat Candida.

Johnson described the three-dimensional approach to vaccinology as giving researchers a clear picture of how a vaccine must physically fit against the surface of the fungus.

The researchers used their findings to design test vaccines that produced positive results in containing the fungus. "Our multi-pronged strategy allowed us to observe a new type of molecular recognition," she said.

Johnson added if the private sector chooses to complete the development of a vaccine it could be 10 years before the drug is available.

Johnson and Bundle were assisted by U of A researcher Jonathan Cartmell and colleagues at the National University of Ireland and University of Georgia. The research was published May 25 in the .

Explore further: New tool identifies therapeutic proteins in a 'snap'

add to favorites email to friend print save as pdf

Related Stories

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Fatal fungal infections resist newest class of drugs

Sep 07, 2011

Fungi that cause severe infections in those with compromised immune systems are resisting the action of the latest group of antifungal drugs. Uncovering their strategies for doing this will lead to more effective treatments, ...

Recommended for you

New tool identifies therapeutic proteins in a 'snap'

Aug 21, 2014

(Phys.org) —In human and bacterial cells, glycosylation – the chemical process of attaching complex sugar molecules to proteins – is as fundamental as it gets, affecting every biological mechanism from cell signaling ...

Treating pain by blocking the 'chili-pepper receptor'

Aug 20, 2014

Biting into a chili pepper causes a burning spiciness that is irresistible to some, but intolerable to others. Scientists exploring the chili pepper's effect are using their findings to develop a new drug ...

Moving single cells around—accurately and cheaply

Aug 19, 2014

Scientists at the Houston Methodist Research Institute have figured out how to pick up and transfer single cells using a pipette—a common laboratory tool that's been tweaked slightly. They describe this ...

The difficult question of Clostridium difficile

Aug 19, 2014

The bacterium Clostridium difficile causes antibiotic-related diarrhoea and is a growing problem in the hospital environment and elsewhere in the community. Understanding how the microbe colonises the hu ...

User comments : 0